TY - THES A1 - Rehlinghaus, Christine T1 - Retrospektive Evaluation der intravenösen Dexamethason- bzw. Methylprednisolon-Pulstherapie bei ausgeprägter Alopecia areata T1 - Retrospective evaluation of intravenous dexamethasone or methylprednisolone pulse therapy for severe alopecia areata N2 - Hintergrund: Bei der Entscheidung für eine intravenöse Kortikosteroid-Pulstherapie bei schweren Formen der AA ist die Abwägung von Therapieaufwand, Nebenwirkungen und Risiken einerseits und der Erfolgsaussicht andererseits von zentraler Bedeutung. Ziel: Ziel dieser retrospektiven Analyse war es daher, die Wirksamkeit und Sicherheit der intravenösen Kortikosteroid-Pulstherapie bei Patient:innen mit ausgeprägter AA klinikintern als qualitätssichernde Maßnahme zu untersuchen, prognostisch bedeutsame Faktoren für den Therapieeffekt zu ermitteln und hierdurch die beste Indikation herauszuarbeiten. Methode: 126 Patient:innen (13 Kinder und Jugendliche) erhielten Dexamethason 100 mg (122 Patienten) oder Methylprednisolon 20-30 mg/kg/KG (max. 1000 mg, 4 Patienten) an drei aufeinanderfolgenden Tagen für ein bis drei Zyklen. Ergebnisse: Patienten mit einer AA partialis bzw. diffusa zeigten im Hinblick auf ein vollständiges oder kosmetisch akzeptables Wiederwachstum die besten Ansprechraten (44,3%, n=43). Unter den Ophiasis-Patienten und den Patienten mit AA totalis/universalis sprach nur etwa ein Viertel auf die Therapie an (Ophiasis 23,8%, n=5; AA totalis/universalis: 25%, n=2). Schwerwiegende unerwünschte Nebenwirkungen wurden nicht beobachtet. Schlussfolgerung: In der vorliegenden Untersuchung ließen sich eine längere Bestandsdauer der Erkrankung und Erkrankungsepisode (über 6 Monate), ein schwerer Ausprägungsgrad (Ophiasis, AA totalis/universalis) und krankheitstypische Nagelveränderungen als wichtige ungünstige prognostische Faktoren nachweisen. Dagegen wirkten sich die untersuchten Kriterien Alter, Geschlecht, atopisches Ekzem und andere Erkrankungen des atopischen Formenkreises, Schilddrüsen- und Autoimmunerkrankungen in der Eigenanamnese sowie AA in der Familienanamnese nicht negativ auf den Behandlungserfolg aus. Patienten mit AA partialis und einer Bestandsdauer der AA von maximal 6 Monaten haben die besten Erfolgsaussichten. N2 - Background: When deciding in favour of intravenous corticosteroid pulse therapy for severe forms of AA, it is of central importance to weigh up the therapeutic effort, side effects and risks on the one hand and the prospects of success on the other. Aim: The aim of this retrospective analysis was therefore to investigate the efficacy and safety of intravenous corticosteroid pulse therapy in patients with pronounced AA within the clinic as a quality assurance measure, to determine prognostically significant factors for the therapeutic effect and thus to identify the best indication. Methods: 126 patients (13 children and adolescents) received dexamethasone 100 mg (122 patients) or methylprednisolone 20-30 mg/kg/KG (max. 1000 mg, 4 patients) on three consecutive days for one to three cycles. Results: Patients with AA partialis or diffusa showed the best response rates in terms of complete or cosmetically acceptable regrowth (44.3%, n=43). Among the ophiasis patients and the patients with AA totalis/universalis, only about a quarter responded to the therapy (ophiasis 23.8%, n=5; AA totalis/universalis: 25%, n=2). No serious adverse events were observed. Conclusion: In the present study, a longer duration of the disease and disease episode (more than 6 months), a severe degree of severity (ophiasis, AA totalis/universalis) and nail changes typical of the disease were found to be important unfavourable prognostic factors. In contrast, the investigated criteria of age, gender, atopic eczema and other atopic diseases, thyroid and autoimmune diseases in the patient's own medical history and AA in the family history did not have a negative effect on the success of treatment. Patients with AA partialis and a maximum duration of AA of 6 months have the best chances of success. KW - Alopecia areata Y1 - 2024 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-360711 ER - TY - JOUR A1 - Scholz, S. L. A1 - Cosgarea, I. A1 - Süßkind, D. A1 - Murali, R. A1 - Möller, I. A1 - Reis, H. A1 - Leonardelli, S. A1 - Schilling, B. A1 - Schimming, T. A1 - Hadaschik, E. A1 - Franklin, C. A1 - Paschen, A. A1 - Sucker, A. A1 - Steuhl, K. P. A1 - Schadendorf, D. A1 - Westekemper, H. A1 - Griewank, K. G. T1 - NF1 mutations in conjunctival melanoma JF - British Journal of Cancer N2 - Background Conjunctival melanoma is a potentially deadly eye tumour. Despite effective local therapies, tumour recurrence and metastasis remain frequent. The genetics of conjunctival melanomas remain incompletely understood. Methods A large cohort of 63 conjunctival melanomas was screened for gene mutations known to be important in other melanoma subtypes by targeted next-generation sequencing. Mutation status was correlated with patient prognosis. Results Frequent mutations in genes activating the MAP kinase pathway were identified. NF1 mutations were most frequent (n = 21, 33%). Recurrent activating mutations were also identified in BRAF (n = 16, 25%) and RAS genes (n = 12, 19%; 11 NRAS and 1 KRAS). Conclusions Similar to cutaneous melanomas, conjunctival melanomas can be grouped genetically into four groups: BRAF-mutated, RAS-mutated, NF1-mutated and triple wild-type melanomas. This genetic classification may be useful for assessment of therapeutic options for patients with metastatic conjunctival melanoma KW - cancer genetics KW - eye cancer Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-233329 VL - 118 ER - TY - JOUR A1 - Kervarrec, Thibault A1 - Samimi, Mahtab A1 - Guyétant, Serge A1 - Sarma, Bhavishya A1 - Chéret, Jérémy A1 - Blanchard, Emmanuelle A1 - Berthon, Patricia A1 - Schrama, David A1 - Houben, Roland A1 - Touzé, Antoine T1 - Histogenesis of Merkel Cell Carcinoma: A Comprehensive Review JF - Frontiers in Oncology N2 - Merkel cell carcinoma (MCC) is a primary neuroendocrine carcinoma of the skin. This neoplasia features aggressive behavior, resulting in a 5-year overall survival rate of 40%. In 2008, Feng et al. identified Merkel cell polyomavirus (MCPyV) integration into the host genome as the main event leading to MCC oncogenesis. However, despite identification of this crucial viral oncogenic trigger, the nature of the cell in which MCC oncogenesis occurs is actually unknown. In fact, several hypotheses have been proposed. Despite the large similarity in phenotype features between MCC tumor cells and physiological Merkel cells (MCs), a specialized subpopulation of the epidermis acting as mechanoreceptor of the skin, several points argue against the hypothesis that MCC derives directly from MCs. Alternatively, MCPyV integration could occur in another cell type and induce acquisition of an MC-like phenotype. Accordingly, an epithelial as well as a fibroblastic or B-cell origin of MCC has been proposed mainly based on phenotype similarities shared by MCC and these potential ancestries. The aim of this present review is to provide a comprehensive review of the current knowledge of the histogenesis of MCC. KW - merkel cell polyomavirus (MCPyV) KW - epithelial KW - fibroblast KW - B cell KW - Merkel cell carcinoma (MCC) KW - histogenesis KW - origin Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-325733 VL - 9 ER -